MedTrace Logo

Photobiomodulation Therapy for the Management of Breast Cancer-related Lymphedema

NCT04690439 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 104

Last updated 2023-02-28

No results posted yet for this study

Summary

Up to one out of five patients with breast cancer will develop lymphedema in the upper extremity after cancer treatment. Patients with breast cancer-related lymphedema (BCRL) suffer from pain, heaviness, tightness, and a decreased range of motion. Photobiomodulation therapy (PBMT) is a non-invasive therapy based on the application of visible and/or near-infrared light produced by a laser diode or a light-emitting diode. The scientifically proven biologic effects of PBM are improved wound healing, and a reduction in pain, inflammation, and oedema. Therefore, the aim of this study is to evaluate the effectiveness of PBMT on the management of BCRL.

Conditions

  • Breast Cancer
  • Breast Cancer Related Lymphedema
  • Lymphedema of Upper Arm

Interventions

DEVICE

Photobiomodulation therapy (PBMT)

The MLS M6 laser from ASA will be used to apply the laser therapy.

PROCEDURE

Manual Lymphatic drainage

Patients will receive twice weekly MLT executed by trained physiotherapist

Sponsors & Collaborators

  • Hasselt University

    collaborator OTHER

  • Jessa Hospital

    lead OTHER

Principal Investigators

  • Jeroen Mebis, MD, PhD · Jessa Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-02-22
Primary Completion
2028-02-29
Completion
2028-02-29

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04690439 on ClinicalTrials.gov